Beta Bionics, Inc. (NASDAQ:BBNX) Given Consensus Recommendation of “Moderate Buy” by Analysts

Beta Bionics, Inc. (NASDAQ:BBNX) has been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, four have assigned a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $20.10.

Several research firms recently issued reports on BBNX. Weiss Ratings raised shares of Beta Bionics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, August 18th. UBS Group initiated coverage on shares of Beta Bionics in a research report on Tuesday, July 28th. They issued a “buy” rating and a $22.00 price target for the company. The Goldman Sachs Group increased their price objective on shares of Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. William Blair began coverage on shares of Beta Bionics in a research report on Friday, August 21st. They set a “market perform” rating on the stock. Finally, Truist Financial lifted their target price on shares of Beta Bionics from $18.00 to $22.00 and gave the company a “buy” rating in a research note on Monday, July 13th.

Beta Bionics Stock Performance

NASDAQ:BBNX opened at $19.54 on Friday. The stock has a 50-day simple moving average of $16.59 and a two-hundred day simple moving average of $13.42. Beta Bionics has a 52-week low of $8.80 and a 52-week high of $32.71. The firm has a market capitalization of $879.10 million, a PE ratio of -11.84 and a beta of 3.13.

Beta Bionics (NASDAQ:BBNX) last posted its quarterly earnings data on Wednesday, July 29th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. Beta Bionics had a negative return on equity of 26.30% and a negative net margin of 61.31%.The firm had revenue of $32.01 million for the quarter. Equities analysts forecast that Beta Bionics will post -2.1 earnings per share for the current fiscal year.

Insider Activity

In other Beta Bionics news, Director Christy Jones sold 2,811 shares of the business’s stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $14.00, for a total value of $39,354.00. Following the sale, the director owned 27,400 shares in the company, valued at $383,600. The trade was a 9.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Hopman sold 5,329 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total transaction of $67,198.69. Following the transaction, the insider directly owned 130,887 shares of the company’s stock, valued at $1,650,485.07. This trade represents a 3.91% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders have sold 36,355 shares of company stock valued at $512,943. Company insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Beta Bionics

Several large investors have recently made changes to their positions in the company. Strs Ohio purchased a new stake in shares of Beta Bionics in the first quarter worth about $29,000. Summit Securities Group LLC purchased a new position in Beta Bionics during the 4th quarter valued at approximately $52,000. Legal & General Group Plc increased its stake in Beta Bionics by 197.4% in the 2nd quarter. Legal & General Group Plc now owns 3,976 shares of the company’s stock worth $58,000 after acquiring an additional 2,639 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Beta Bionics by 1,075.7% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,987 shares of the company’s stock worth $61,000 after acquiring an additional 1,818 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Beta Bionics during the 1st quarter worth approximately $95,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.